UGT1A1 gene product metabolic activity interpretation in Blood or Tissue Qualitative by Molecular genetics method

UGT1A1 gene prod met act imp Bld/T-Imp

Definition

The UGT1A1 gene product metabolic activity interpretation is determined by the reporting lab and returned with the structured test results. The Preferred Answer list associated with this term is based on the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for reporting UGT1A1 gene product metabolic activity (phenotype), which apply to both genetic and enzymatic assays (this LOINC term represents a genetic assay). This specific interpretation would be considered a separate observation made by the lab in addition to the primary reported results (e.g., genotype or measured activity level) and it could be included with other assay-specific observations, which would ideally support the interpretation value. [https://cpicpgx.org/resources.html]

Activ; Actvty; BILIQTL1; Blood; Crigler-Najjar syndrome, type I; Drug metabolism; Gene prod met act imp; Gilbert Syndrome; GNT1; HUG-BR1; Impression; Impression/interpretation of study; Impressions; Interp; Interpret; Interpretation; Interpt; Intrp; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.PHARMG; Movements; Ordinal; PCR; Phenotype; Point in time; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; UDP glucuronosyltransferase 1 family, polypeptide A1; UDP glycosyltransferase 1 family, polypeptide A1 gene; UDPGT; UDPGT 1-1; UGT1; UGT1A; UGT1A1 gene prod met act imp; UGT1A5; WB; Whole blood; Whole blood or Tissue

5 further terms